STAT3 and prostate cancer: Recently, other SH2 domain inhibitors (323-1 and 323-2) have been developed and lead to the downregulation of STAT3 downstream genes, like the MCL1 apoptosis regulator (MCL1) and cyclin D1 (CCND1), in DU145 prostate cancer cells [66].